Browse ARHGEF18

Summary
SymbolARHGEF18
NameRho/Rac guanine nucleotide exchange factor (GEF) 18
Aliases P114-RhoGEF; KIAA0521; MGC15913; Rho-specific guanine nucleotide exchange factor p114; 114 kDa Rho-specific ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Cytoplasm, cytoskeleton Apical cell membrane
Domain PF00169 PH domain
PF00621 RhoGEF domain
Function

Acts as guanine nucleotide exchange factor (GEF) for RhoA GTPases. Its activation induces formation of actin stress fibers. Also act as a GEF for RAC1, inducing production of reactive oxygen species (ROS). Does not act as a GEF for CDC42. The G protein beta-gamma (Gbetagamma) subunits of heterotrimeric G proteins act as activators, explaining the integrated effects of LPA and other G-protein coupled receptor agonists on actin stress fiber formation, cell shape change and ROS production. Required for EPB41L4B-mediated regulation of the circumferential actomyosin belt in epithelial cells (PubMed:22006950).

> Gene Ontology
 
Biological Process GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007265 Ras protein signal transduction
GO:0007266 Rho protein signal transduction
GO:0008360 regulation of cell shape
GO:0022604 regulation of cell morphogenesis
GO:0035023 regulation of Rho protein signal transduction
GO:0046578 regulation of Ras protein signal transduction
GO:0051056 regulation of small GTPase mediated signal transduction
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
Molecular Function GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0005089 Rho guanyl-nucleotide exchange factor activity
Cellular Component GO:0016324 apical plasma membrane
GO:0045177 apical part of cell
> KEGG and Reactome Pathway
 
KEGG hsa04530 Tight junction
Reactome R-HSA-204998: Cell death signalling via NRAGE, NRIF and NADE
R-HSA-416482: G alpha (12/13) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-193648: NRAGE signals death through JNK
R-HSA-194840: Rho GTPase cycle
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-194315: Signaling by Rho GTPases
R-HSA-170834: Signaling by TGF-beta Receptor Complex
R-HSA-166520: Signalling by NGF
R-HSA-2173791: TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
R-HSA-193704: p75 NTR receptor-mediated signalling
Summary
SymbolARHGEF18
NameRho/Rac guanine nucleotide exchange factor (GEF) 18
Aliases P114-RhoGEF; KIAA0521; MGC15913; Rho-specific guanine nucleotide exchange factor p114; 114 kDa Rho-specific ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ARHGEF18 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolARHGEF18
NameRho/Rac guanine nucleotide exchange factor (GEF) 18
Aliases P114-RhoGEF; KIAA0521; MGC15913; Rho-specific guanine nucleotide exchange factor p114; 114 kDa Rho-specific ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ARHGEF18 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.65 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolARHGEF18
NameRho/Rac guanine nucleotide exchange factor (GEF) 18
Aliases P114-RhoGEF; KIAA0521; MGC15913; Rho-specific guanine nucleotide exchange factor p114; 114 kDa Rho-specific ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ARHGEF18 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0710.741
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2280.89
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0450.971
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.130.704
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.20.916
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0410.986
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3010.37
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.40.78
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.130.938
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5560.61
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4320.791
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0110.897
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ARHGEF18 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.67.4-4.80.565
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolARHGEF18
NameRho/Rac guanine nucleotide exchange factor (GEF) 18
Aliases P114-RhoGEF; KIAA0521; MGC15913; Rho-specific guanine nucleotide exchange factor p114; 114 kDa Rho-specific ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ARHGEF18. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolARHGEF18
NameRho/Rac guanine nucleotide exchange factor (GEF) 18
Aliases P114-RhoGEF; KIAA0521; MGC15913; Rho-specific guanine nucleotide exchange factor p114; 114 kDa Rho-specific ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ARHGEF18. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ARHGEF18.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolARHGEF18
NameRho/Rac guanine nucleotide exchange factor (GEF) 18
Aliases P114-RhoGEF; KIAA0521; MGC15913; Rho-specific guanine nucleotide exchange factor p114; 114 kDa Rho-specific ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ARHGEF18. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolARHGEF18
NameRho/Rac guanine nucleotide exchange factor (GEF) 18
Aliases P114-RhoGEF; KIAA0521; MGC15913; Rho-specific guanine nucleotide exchange factor p114; 114 kDa Rho-specific ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ARHGEF18 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolARHGEF18
NameRho/Rac guanine nucleotide exchange factor (GEF) 18
Aliases P114-RhoGEF; KIAA0521; MGC15913; Rho-specific guanine nucleotide exchange factor p114; 114 kDa Rho-specific ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ARHGEF18 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolARHGEF18
NameRho/Rac guanine nucleotide exchange factor (GEF) 18
Aliases P114-RhoGEF; KIAA0521; MGC15913; Rho-specific guanine nucleotide exchange factor p114; 114 kDa Rho-specific ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ARHGEF18 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.